- Home
- LVTX vs VRCA Comparison
LVTX vs VRCA Comparison
Compare LVTX & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- VRCA
- Stock Information
- Founded
- LVTX 2016
- VRCA 2013
- Country
- LVTX Netherlands
- VRCA United States
- Employees
- LVTX N/A
- VRCA N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- VRCA Health Care
- Exchange
- LVTX Nasdaq
- VRCA Nasdaq
- Market Cap
- LVTX 40.8M
- VRCA 40.6M
- IPO Year
- LVTX 2021
- VRCA 2018
- Fundamental
- Price
- LVTX $1.58
- VRCA $4.42
- Analyst Decision
- LVTX Hold
- VRCA Hold
- Analyst Count
- LVTX 4
- VRCA 5
- Target Price
- LVTX $1.58
- VRCA $60.00
- AVG Volume (30 Days)
- LVTX 437.0K
- VRCA 592.0K
- Earning Date
- LVTX 08-13-2025
- VRCA 11-03-2025
- Dividend Yield
- LVTX N/A
- VRCA N/A
- EPS Growth
- LVTX N/A
- VRCA N/A
- EPS
- LVTX N/A
- VRCA N/A
- Revenue
- LVTX $4,990,000.00
- VRCA $14,704,000.00
- Revenue This Year
- LVTX N/A
- VRCA $332.45
- Revenue Next Year
- LVTX N/A
- VRCA $12.85
- P/E Ratio
- LVTX N/A
- VRCA N/A
- Revenue Growth
- LVTX N/A
- VRCA 5.72
- 52 Week Low
- LVTX $0.85
- VRCA $3.82
- 52 Week High
- LVTX $2.09
- VRCA $17.38
- Technical
- Relative Strength Index (RSI)
- LVTX 59.32
- VRCA 44.09
- Support Level
- LVTX $1.53
- VRCA $4.17
- Resistance Level
- LVTX $1.64
- VRCA $4.75
- Average True Range (ATR)
- LVTX 0.04
- VRCA 0.30
- MACD
- LVTX 0.00
- VRCA 0.05
- Stochastic Oscillator
- LVTX 87.12
- VRCA 45.56
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.